Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 11/20 | 0.61 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.46 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 6/20 | 0.42 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.42 |
| ▸ | VNN1 | O95497 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12953887 | 0.91 | GSK3B (0.75) | GSK3BCDK2CCNE1 | |
| SCHEMBL13289043 | 0.90 | GSK3B (0.63) | GSK3BCHEK1CDK2CCNE1VNN1 | |
| SCHEMBL13288831 | 0.88 | GSK3B (0.59) | GSK3BCHEK1CDK9CDK2CCNE1 | |
| SCHEMBL13288832 | 0.87 | GSK3B (0.58) | GSK3BCHEK1CDK2CCNE1 | |
| SCHEMBL13288814 | 0.87 | GSK3B (0.61) | GSK3BCHEK1CDK2CCNE1 | |
| SCHEMBL13305370 | 0.87 | GSK3B (0.61) | GSK3BCHEK1CDK2CCNE1VNN1 | |
| SCHEMBL12953848 | 0.87 | GSK3B (0.61) | GSK3BCHEK1CDK2CCNE1 | |
| SCHEMBL13289192 | 0.87 | GSK3B (0.59) | GSK3BCHEK1CDK9CDK2CCNE1 | |
| SCHEMBL13118840 | 0.86 | GSK3B (0.74) | GSK3BCDK2CCNE1 | |
| SCHEMBL14545867 | 0.86 | GSK3B (0.59) | GSK3BCHEK1CDK9CDK2CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2194058-A1 | Pyrazolopyrimidines suitable for the treatment of cancer diseases | SCHERING CORPORATION (US) | 2010-06-09 | — | — | EP | disclosed |
| US-20070225270-A1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225270-A1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDKN1A, CDK1 | GSK3B 749/4885CHEK1 58/4885CDK9 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.